Eyenovia Provides Updates On Its Myopia Phase III Program And Its 2 FDA Approved Commercial Products, Mydcombi And Clobetasol
Eyenovia Provides Updates On Its Myopia Phase III Program And Its 2 FDA Approved Commercial Products, Mydcombi And Clobetasol
Eyenovia提供了其近视三期计划及其2种经美国食品药品管理局批准的商用产品Mydcombi和Clobetasol的最新情况
Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market, MicroPine
在价值数十亿美元的儿科进行性近视市场中，加速开发其后期候选产品MicroPine仍步入正轨
Preparing for a 3Q 2024 launch of the first new ophthalmic steroid in 15 years, clobetasol propionate ophthalmic suspension 0.05%, for the treatment of inflammation and pain following ocular surgery
为2024年第三季度推出15年来首款新的眼科类固醇——丙酸氯倍他索眼药混悬液做准备，用于治疗眼部手术后的炎症和疼痛，0.05％
Company to host conference call and webcast today, May 15th, at 4:30 pm ET
公司将于今天，美国东部时间5月15日下午 4:30 举办电话会议和网络直播
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。